Difficulties in laboratory diagnosis of coexistent lupus anticoagulant and factor VIII inhibitors: case report and review of literature

被引:1
作者
Belhadj, Maroua [1 ,2 ]
Cheikhrouhou, Meriem [1 ,2 ]
Guermazi, Sami [1 ,2 ]
机构
[1] Charles Nicolle Hosp, Lab hematol, Tunis, Tunisia
[2] Univ Tunis El Manar, Fac Med Tunis, Tunis 1007, Tunisia
关键词
lupus anticoagulant; Factor VIII inhibitors; activated partial thromboplastin time; case report; acquired hemophilia; antiphospholipid antibodies; ACQUIRED HEMOPHILIA-A; COAGULATION-FACTORS; MIXING TESTS; GUIDELINES; ANTIBODIES; UPDATE; CRITERIA; ASSAY; RARE;
D O I
10.1684/abc.2023.1825
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Whereas lupus anticoagulant (LA) and anti -factor VIII (anti-VIII) antibody are both acquired autoimmune coagulation inhibitors, they exhibit different pathophysiologic mechanisms and opposite clinical manifestations. Distinguishing between these two inhibitors is therefore essential for optimizing appropriate management. Harboring both antibodies, which is a rare condition, is of a challenging and confounding laboratory work-up. Case presentation: We illustrate a case report of a 39-year-old man admitted for the management of recurrent deep-vein thrombosis. Curiously, the initial physical examination revealed several hematoma and bruises of varying sizes. Biologically, a prolonged activated partial thromboplastin time (APTT) was objectified and was not corrected by the mixing study. The following detection of synchronous LA and anti -VIII was made using specific assays. Conclusions: Through this case, we illustrate the complexity of diagnosing coexistent LA and FVIII inhibitors. In fact, the biological hallmark of both inhibitors is an isolated prolonged APTT that does not correct by the mixing study. Despite the progress in LA and anti-VIII assays and the ongoing updating of standardized recommendations, the lack of specific tests for LA and the limited availability of VIII quantification tests other than the clot-based assays make it difficult to distinguish adequately between the two inhibitors. Therefore, it is crucial to correlate test results with clinical features and patient evaluation.
引用
收藏
页码:417 / 423
页数:7
相关论文
共 46 条
  • [1] Prolonged Activated Partial Thromboplastin Time: Difficulties in Discriminating Coexistent Factor VIII Inhibitor and Lupus Anticoagulant
    Ames, Paul R. J.
    Graf, Maria
    Archer, Jeremy
    Scarpato, Nicola
    Iannaccone, Luigi
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2015, 21 (02) : 149 - 154
  • [2] MOLECULAR-BASIS OF FACTOR-VIII INHIBITION BY HUMAN-ANTIBODIES - ANTIBODIES THAT BIND TO THE FACTOR-VIII LIGHT CHAIN PREVENT THE INTERACTION OF FACTOR-VIII WITH PHOSPHOLIPID
    ARAI, M
    SCANDELLA, D
    HOYER, LW
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (06) : 1978 - 1984
  • [3] Bain BJ, 2022, Lewis Practical Haematology
  • [4] Blanco AN, 1998, AM J HEMATOL, V58, P248, DOI 10.1002/(SICI)1096-8652(199807)58:3<248::AID-AJH18>3.0.CO
  • [5] 2-5
  • [6] Blanco AN, 2002, HAEMATOLOGICA, V87, P271
  • [7] BRANDT JT, 1995, THROMB HAEMOSTASIS, V74, P1185
  • [8] Chang SH, 2002, AM J CLIN PATHOL, V117, P62
  • [9] Clinical and Laboratory Standards Institute (CLSI), H47-A2: One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test
  • [10] Approved Guideline, VSecond, P14